Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after platinum-based treatment: EAST-LC

被引：0

作者：

Shunichi Sugawara

Kazuhiko Nakagawa

Nobuyuki Yamamoto

Hiroshi Nokihara

Yuichiro Ohe

Makoto Nishio

Toshiaki Takahashi

Koichi Goto

Makoto Maemondo

Yukito Ichinose

Takashi Seto

Hiroshi Sakai

Akihiko Gemma

Fumio Imamura

Masato Shingyoji

Hideo Saka

Akira Inoue

Koji Takeda

Isamu Okamoto

Katsuyuki Kiura

Satoshi Morita

Tomohide Tamura

机构：

[1] Sendai Kousei Hospital,Department of Pulmonary Medicine

[2] Kindai University,Department of Medical Oncology, Faculty of Medicine

[3] Wakayama Medical University,Third Department of Internal Medicine

[4] National Cancer Center Hospital,Department of Thoracic Oncology

[5] The Cancer Institute Hospital of Japanese Foundation for Cancer Research,Department of Thoracic Medical Oncology

[6] Shizuoka Cancer Center,Division of Thoracic Oncology

[7] National Cancer Center Hospital East,Department of Thoracic Oncology

[8] Miyagi Cancer Center,Department of Respiratory Medicine

[9] Clinical Research Institute,Department of Cancer Information Research, National Kyushu Cancer Center

[10] National Kyushu Cancer Center,Department of Thoracic Oncology

[11] Saitama Cancer Center,Department of Thoracic Oncology

[12] Nippon Medical School,Department of Pulmonary Medicine and Oncology, Graduate School of Medicine

[13] Osaka International Cancer Institute,Department of Thoracic Oncology

[14] Chiba Cancer Center,Division of Respirology

[15] National Hospital Organization Nagoya Medical Center,Department of Respiratory Medicine and Medical Oncology

[16] Tohoku University School of Medicine,Department of Palliative Medicine

[17] Osaka City General Hospital,Department of Medical Oncology

[18] Kyushu University,Research Institute for Diseases of the Chest, Graduate School of Medical Sciences

[19] Okayama University Graduate School of Medicine,Department of Hematology, Oncology, and Respiratory Medicine

[20] Kyoto University Graduate School of Medicine,Department of Biomedical Statistics and Bioinformatics

[21] St Luke’s International Hospital,Thoracic Center

来源：

International Journal of Clinical Oncology | 2019年 / 24卷

关键词：

Tegafur–gimeracil–oteracil; Second line; Third line; Chemotherapy; Japan; Phase III;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：485 / 493

页数：8

共 50 条

[21] Phase I/II Study of Docetaxel and S-1 in Previously-Treated Patients with Advanced Non-Small Cell Lung Cancer: LOGIK0408
Takayama, Koichi
Uchino, Junji
Fujita, Masaki
Tokunaga, Shoji
Imanaga, Tomotoshi
Morinaga, Ryotaro
Ebi, Noriyuki
Saeki, Sho
Matsukizono, Kazuya
Wataya, Hiroshi
Yamada, Tadaaki
Nakanishi, Yoichi
JOURNAL OF CLINICAL MEDICINE, 2019, 8 (12)
[22] The importance of histology in patient selection for platinum-based neoadjuvant treatment in non-small cell lung cancer
Kocaman, Gokhan
Kahya, Yusuf
Koksoy, Elif Berna
Elhan, Atilla Halil
Yenigun, Mustafa Bulent
Ozkan, Murat
Yuksel, Cabir
Enon, Serkan
Cangir, Ayten Kayi
Kutlay, Hakan
Akal, Rifat Murat
TURK GOGUS KALP DAMAR CERRAHISI DERGISI-TURKISH JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2025,
[23] Serum APE1 as a predictive marker for platinum-based chemotherapy of non-small cell lung cancer patients
Zhang, Shiheng
He, Le
Dai, Nan
Guan, Wei
Shan, Jinlu
Yang, Xueqin
Zhong, Zhaoyang
Qing, Yi
Jin, Feng
Chen, Chuan
Yang, Yuxin
Wang, Hongyi
Baugh, Laura
Tell, Gianluca
Wilson, David M., III
Li, Mengxia
Wang, Dong
ONCOTARGET, 2016, 7 (47) : 77482 - 77494
[24] Phase II study of weekly docetaxel and cisplatin in patients with non-small cell lung cancer
Kaira, K
Takise, A
Minato, K
Iwasaki, Y
Ishihara, S
Takei, Y
Tsuchiya, S
Saito, R
Sato, K
Mori, M
ANTI-CANCER DRUGS, 2005, 16 (04) : 455 - 460
[25] Docetaxel and cyclooxygenase-2 inhibition with celecoxib for advanced non-small cell lung cancer progressing after platinum-based chemotherapy: a multicenter phase II trial
Nugent, FW
Mertens, WC
Graziano, S
Levitan, N
Collea, R
Gajra, A
Marshall, J
McCann, J
LUNG CANCER, 2005, 48 (02) : 267 - 273
[26] A phase II study of S-1 monotherapy as second-line treatment for advanced non-small cell lung cancer
Totani, Yoshitaka
Saito, Yuji
Hayashi, Masamichi
Tada, Toshihiko
Kohashi, Yasuo
Mieno, Yuki
Kato, Atsushi
Imizu, Hiromi
Yoneda, Yukiko
Hoshino, Tami
Uchiyama, Yasuhiro
Takeuchi, Yasuo
Okazawa, Mitsushi
Sakakibara, Hiroki
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (06) : 1181 - 1185
[27] Randomized phase III study of docetaxel versus docetaxel plus intercalated erlotinib in patients with relapsed non-squamous non-small cell lung carcinoma
Steendam, Christi M. J.
Peric, Robert
van Walree, Nico C.
Youssef, Magdolen
Schramel, Franz M. N. H.
Brocken, Pepijn
van Putten, John W. G.
van der Noort, Vincent
Veerman, G. D. Marijn
Koolen, Stijn L. W.
Groen, Harry J. M.
Dingemans, Anne-Marie C.
Mathijssen, Ron H. J.
Smit, Egbert F.
Aerts, Joachim G. J., V
LUNG CANCER, 2021, 160 : 44 - 49
[28] Phase I study of daily S-1 combined with weekly irinotecan in patients with advanced non-small cell lung cancer
Ishimoto, Osamu
Ishida, Takashi
Honda, Yoshihiro
Munakata, Mitsuru
Sugawara, Shunichi
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2009, 14 (01) : 43 - 47
[29] Phase II Study of S-1 and Paclitaxel Combination Therapy in Patients with Previously Treated Non-Small Cell Lung Cancer
Chihara, Yusuke
Yoshimura, Akihiro
Date, Koji
Takemura, Yoshizumi
Tamiya, Nobuyo
Kohno, Yoshihito
Imabayashi, Tatsuya
Takeuchi, Mayumi
Kaneko, Yoshiko
Yamada, Tadaaki
Ueda, Mikio
Arimoto, Taichiro
Uchino, Junji
Iwasaki, Yoshinobu
Takayama, Koichi
ONCOLOGIST, 2019, 24 (08) : 1033 - +
[30] Phase I/II Study of Inhaled Doxorubicin Combined with Platinum-Based Therapy for Advanced Non-Small Cell Lung Cancer
Otterson, Gregory A.
Villalona-Calero, Miguel A.
Hicks, William
Pan, Xueliang
Ellerton, John A.
Gettinger, Scott N.
Murren, John R.
CLINICAL CANCER RESEARCH, 2010, 16 (08) : 2466 - 2473

← 1 2 3 4 5 →